China Pharma Holdings (CPHI) Free Cash Flow Growth (1y) (2011 - 2026)
Powered by 
Analysis
China Pharma Holdings (CPHI) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 157.32% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | -36.24% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 77.03% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -11.32% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 125.17% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 107.90% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 1,829.52% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 58.76% |
| 10 | China Pharma Holdings | 31.39 Mn | 31.08 Mn | 83,566.00 | -111.96% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -111.96% |
| Mar 31, 2026 | 58.11% |
| Dec 31, 2025 | -45.73% |
| Sep 30, 2025 | -443.23% |
| Jun 30, 2025 | 477.27% |
| Mar 31, 2025 | 77.44% |
| Dec 31, 2024 | 1,139.96% |
| Sep 30, 2024 | -104.01% |
| Jun 30, 2024 | 65.68% |
| Mar 31, 2024 | 58.57% |
| Dec 31, 2023 | -104.39% |
| Sep 30, 2023 | 2,911.59% |
| Jun 30, 2023 | 58.37% |
| Mar 31, 2023 | -60.33% |
| Dec 31, 2022 | 398.22% |
| Sep 30, 2022 | 96.14% |
| Jun 30, 2022 | -175.31% |
| Mar 31, 2022 | -218.09% |
| Dec 31, 2021 | -136.16% |
| Sep 30, 2021 | -79.16% |